LESINIDASE ALFA
Mucopolysaccharidosis IIIB
Alexion Pharmaceuticals, Inc.protein_peptidePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Mucopolysaccharidosis IIIB cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Raav2/5-Hnaglu UniQure Biopharma B.V. | Phase 1/2 | CCC |
Raav9.Cmv.Hnaglu Abeona Therapeutics, Inc | Phase 1/2 | CCC |
ax 250 Allievex Corporation | Phase 4 | NR |
Tralesinidase Alfa Spruce Biosciences | Phase 3 | NR |
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →